Viking Therapeutics, Inc.(VKTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VKTX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Viking Therapeutics, Inc. (VKTX), a Healthcare sector company. VKTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of VKTX by reported 13-F value include FMR, BlackRock, STATE STREET, based on the most recent SEC filings. VKTX trades on the Nasdaq exchange and files with the SEC under CIK 1607678. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Viking Therapeutics, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-128.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-227.1% YoYOperating Income
-160.6% YoYEPS (Diluted)
-215.8% YoYTotal Assets
-21.2% YoYOp. Cash Flow
-217.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-359.6M -227.1% | $-110.0M -28.0% | $-85.9M -24.7% | $-68.9M -25.2% | $-55.0M -39.2% | $-39.5M |
| Operating Income | $-393.3M -160.6% | $-150.9M -49.7% | $-100.8M -43.3% | $-70.4M -26.4% | $-55.7M -30.5% | $-42.7M |
| EPS (Diluted) | $-3.19 -215.8% | $-1.01 -11.0% | $-0.91 -1.1% | $-0.90 -26.8% | $-0.71 | — |
| Total Assets | $715.7M -21.2% | $908.3M +146.5% | $368.5M +118.7% | $168.5M -20.0% | $210.7M -17.9% | $256.5M |
| Operating Cash Flow | $-278.7M -217.4% | $-87.8M -19.6% | $-73.4M -51.6% | $-48.4M -1.7% | $-47.6M -118.5% | $-21.8M |
Get alerted when VKTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Viking Therapeutics, Inc. including:
Top Institutional Holders of VKTX
FMR LLC
$247.2M6,335,756 shBlackRock, Inc.
$241.5M6,189,649 shSTATE STREET CORP
$218.7M5,606,394 shVANGUARD CAPITAL MANAGEMENT LLC
$197.1M5,053,663 shVANGUARD PORTFOLIO MANAGEMENT LLC
$174.9M4,484,263 shTWO SIGMA INVESTMENTS, LP
$153.6M3,937,414 shMORGAN STANLEY
$136.0M3,486,040 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$113.4M2,906,500 shAMERIPRISE FINANCIAL INC
$84.1M2,156,083 shGEODE CAPITAL MANAGEMENT, LLC
$81.9M2,097,981 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $247.2M | 6,335,756 |
| BlackRock, Inc. | $241.5M | 6,189,649 |
| STATE STREET CORP | $218.7M | 5,606,394 |
| VANGUARD CAPITAL MANAGEMENT LLC | $197.1M | 5,053,663 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $174.9M | 4,484,263 |
| TWO SIGMA INVESTMENTS, LP | $153.6M | 3,937,414 |
| MORGAN STANLEY | $136.0M | 3,486,040 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $113.4M | 2,906,500 |
| AMERIPRISE FINANCIAL INC | $84.1M | 2,156,083 |
| GEODE CAPITAL MANAGEMENT, LLC | $81.9M | 2,097,981 |
More Healthcare Companies
View all Healthcare →Put VKTX on your watchlist
Track score changes the day Viking Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VKTX a good stock to buy?
13F Pro's AI-powered analysis of Viking Therapeutics, Inc. (VKTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VKTX are available on the VKTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VKTX is classified as a mid company.
Which hedge funds own VKTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VKTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Viking Therapeutics, Inc.'s investment landscape.